Biotech Values

[poorgradstudent]

CELG and ONXX are also many magnitudes higher in market cap.

I'm just picking on Blade, because i know he wouldn't touch a >$5 per share stock with a 100 foot pole Heck, he had already bought it!

It seems like an ok risk to take if you have a diversified portfolio. Requires a bit of a gambling fever though. The way forward for ET is not clear, so in a sense they're restarting with MF which therefore increases the risk. Will the results in a less sick ET patient population really translate to the MF population? I've found some papers looking at the relationship between JAK mutation and telomerase activity, but they're not abundant.

I also need to dig up my old genta notes to see if there were effects of longer duration phosphorothioate oligo administration. The presenter was talking about NSCLC but I'm not so sure that solid tumours are the place to go with this type of drug backbone.